Trinity Biotech (TRIB) Capital Leases (2016 - 2025)

Trinity Biotech's Capital Leases history runs 10 years deep, the most recent figure standing at $10.8 million for Q4 2025.

• In Q4 2025, Capital Leases rose 3.46% year-over-year to $10.8 million; the TTM figure through Dec 2025 stood at $10.8 million (up 3.46% YoY), while the FY2025 annual figure was $10.8 million, up 3.46% from the prior year.
• Capital Leases came in at $10.8 million for Q4 2025 at Trinity Biotech, up from $10.5 million in the prior quarter.
• In the past five years, Capital Leases ranged from a high of $13.9 million in Q4 2021 to a low of $10.5 million in Q4 2024.
• A 5-year average of $11.7 million and a median of $10.9 million in 2023 frame the typical range for Capital Leases.
• Across the five-year window, Capital Leases slipped 16.42% in 2021 and grew 3.46% in 2025, its largest moves.
• Trinity Biotech's Capital Leases stood at $13.9 million in 2021, then slipped by 11.53% to $12.3 million in 2022, then slipped by 11.37% to $10.9 million in 2023, then retreated by 3.63% to $10.5 million in 2024, then advanced by 3.46% to $10.8 million in 2025.
• According to Business Quant data, Capital Leases over the past three periods registered $10.8 million, $10.5 million, and $10.9 million for Q4 2025, Q4 2024, and Q4 2023 respectively.

Peer Comparison